Given the $10 a dose revenue, I'd call it a failure in the process rather than a mistake. That it was possible is the bigger problem than it happening. And the

Given the $10 a dose revenue, I'd call it a failure in the process rather than a mistake. That it was possible is the bigger problem than it happening. And then there's the much greater value of the doses once they have been administered.